May 7, 2025 updated by: CytoDyn, Inc. A Phase Two
Post# of 154853

A Phase Two Study Evaluating Two Doses of Leronlimab (Pro 140) In Combination With Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants With CCR5+, Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCR)
Source read in full
https://ichgcp.net/clinical-trials-registry/NCT06699836

